Navigation Links
Unigene to Present at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference
Date:2/27/2012

BOONTON, N.J., Feb. 27, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced the Company's Vice President of Research and Development, Nozer Mehta, Ph.D., will be presenting at IBC's 4th Annual AsiaTIDES Oligonucleotide and Peptide® Conference being held at the Sheraton Miyako Hotel in Tokyo, Japan.

The TIDES Oligonucleotide and Peptide Conferences are the premier forums focused on oligonucleotide and peptide-based therapeutics, serving as an annual gathering point for the leading companies, academics and researchers in the field.  As a key industry opinion and thought leader, Dr. Mehta will address the conference attendees on topics of critical importance to the growth of peptide therapeutics.

Recent Advances in Routes of Delivery for Peptide Pharmaceuticals

Plenary keynote presentation

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Tuesday, February 28, at 4:30pm JST (Tuesday, February 28, at 2:30am EST)
  • Focus: Peptides in advanced stages of clinical development with oral or transdermal technologies

Clinical Development of a Solid Dosage Oral Formulation for the 32 Amino Acid Peptide Salmon Calcitonin

  • Given by: Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene
  • Date & Time: Thursday, March 1, at 12:00pm JST (Wednesday, February 29, at 10:00pm EST)
  • Focus: Advantages of Unigene's oral delivery technology demonstrated in a Phase 3 clinical study for salmon calcitonin, including an improved variability profile and limited food effects on the biological activity of the peptide

"I welcome the opportunity to provide the attendees of AsiaTIDES with a comprehensive review of recent advancements in the delivery of peptides, most notably Unigene's validated and most clinically advanced oral peptide delivery technology platform, as well as the company's late-stage and feasibility oral peptide programs developed via our Peptelligence™ platform," said Dr. Mehta. "Advances in the delivery of peptide therapeutics, particularly oral peptide technologies, have the opportunity to redefine the treatment regimen and market for numerous debilitating, chronic conditions.  Given this opportunity, the pharmaceutical industry is directing increasing attention and resources to companies and institutions that are developing next-generation peptide compounds, making a conference like AsiaTIDES an extremely valuable scientific and business development event."

About Unigene Laboratories, Inc.:

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

Media Contact:
Tiberend Strategic Advisors, Inc.
Jason Rando / Andrew Mielach
212-827-0020
jrando@tiberend.com / amielach@tiberend.com


'/>"/>
SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene Announces Key Appointments as Biotechnologies Strategic Business Unit Continues to Grow in 2012
2. Unigene Laboratories Granted US Patent for Peptide-Based Technology for Treatment of Obesity
3. Unigene Provides 2012 Business Outlook
4. Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9
5. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
6. Unigene Strengthens Board with the Appointment of Walgreens Executive, Thomas J. Sabatino, Jr.
7. Unigene Reports Third Quarter 2011 Financial Results
8. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
9. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
10. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
11. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
Breaking Medicine News(10 mins):